Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Integrin α7 Defines a Profibrotic and Proinflammatory Adipose Stromal Population Targeted for Nanoparticle PAI-1 Gene Silencing in Obesity.

Mota L., Zhang D., Ortiz YS., Gonzalez FZ., Chung E., Dang C.

Animal Study, published in Mol Ther (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mol Ther (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42576383
DOI
10.1016/j.ymthe.2026.08.005

Abstract (original English)

Obesity-associated metabolic dysfunction is driven not only by adipocyte expansion but also by pathological remodeling of adipose tissue mediated by distinct stromal cell subpopulations. However, the lack of strategies to selectively interrogate and therapeutically modulate these pathogenic cells has limited clinical progress. Here, we identify integrin α7 (ITGA7)-expressing adipose stromal cells (ASCs) as a proinflammatory and profibrotic population that contributes to adipose tissue dysfunction in obesity and introduce a targeted nanotherapy to selectively reprogram their inflammatory signaling. ITGA7 high ASCs from obese white adipose tissue display a profibrotic, proinflammatory phenotype with impaired adipogenic capacity, exacerbated by inflammatory stress. To selectively target this subset, we engineered lipid-coated mesoporous silica nanoparticles functionalized with anti-ITGA7 antibodies, which exhibit preferential uptake by ITGA7 high ASCs in vitro and in vivo. Leveraging this platform, we delivered siRNA against plasminogen activator inhibitor-1 (PAI-1), a key regulator of obesity-associated inflammation and fibrosis. In obese mice, ITGA7-targeted siRNA nanotherapy selectively accumulates in white adipose tissue and effectively silences PAI-1 expression at both the tissue level and within ITGA7 high ASCs. Together, these findings establish ITGA7 as a therapeutically a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.